CRABP2 and neoplasm: We found that liensinine aggravated tumor growth when administered in combination with CRABP2‐Mut‐NLS overexpression (Figure 6E,F; Figure S5C, Supporting Information), with consistent results observed in vitro (Figure S5D–G, Supporting Information).